These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 12755010)

  • 1. [Positive inotropic agents].
    Asanoi H
    Nihon Rinsho; 2003 May; 61(5):827-32. PubMed ID: 12755010
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Refractory heart failure. Positive inotropes and beta blockers: alternative or complementary treatments?].
    Sabbadini G; Ciaccheri M; Castelli G; Sinagra G; Di Lenarda A
    Ital Heart J Suppl; 2002 Aug; 3(8):804-11. PubMed ID: 12407835
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [How and to what extent has beta-blocker treatment been established for chronic heart failure?].
    Yokota Y
    J Cardiol; 1996 Aug; 28(2):99-112. PubMed ID: 8814528
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Drug therapy of cardiac insufficiency: status 1995].
    Rickenbacher P; Buser P; Osswald S; Pfisterer M
    Schweiz Med Wochenschr; 1996 May; 126(21):933-45. PubMed ID: 8693314
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Combination therapy of beta blockers for heart failure].
    Watanabe M; Hirata Y
    Nihon Rinsho; 2007 May; 65 Suppl 5():129-33. PubMed ID: 17571376
    [No Abstract]   [Full Text] [Related]  

  • 6. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug therapy of chronic heart failure in the elderly: the current state of clinical-trial evidence.
    Dulin BR; Krum H
    Curr Opin Cardiol; 2006 Jul; 21(4):393-9. PubMed ID: 16755210
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Concomitant use of a positive inotropic agent to create a bridge to the successful initiation of beta-blocker therapy in patients with heart failure: a proposal for a trial.
    Zampino M; O'Connor CM; Gattis WA; Adams KF; Gheorghiade M
    Am Heart J; 2003 Feb; 145(2 Suppl):S62-6. PubMed ID: 12594456
    [No Abstract]   [Full Text] [Related]  

  • 9. [Trends in pharmacological treatment of congestive heart failure].
    Halawa B
    Pol Merkur Lekarski; 1999 Mar; 6(33):152-6. PubMed ID: 10365602
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Pharmacological treatment of heart failure].
    Kohno M
    Nihon Rinsho; 2003 Apr; 61 Suppl 4():660-6. PubMed ID: 12735047
    [No Abstract]   [Full Text] [Related]  

  • 11. [Drug treatment of cardiac insufficiency with systolic dysfunction].
    Follath F
    Praxis (Bern 1994); 1997 Feb; 86(7):254-7. PubMed ID: 9139344
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Left ventricular assist device as destination for patients undergoing intravenous inotropic therapy: a subset analysis from REMATCH (Randomized Evaluation of Mechanical Assistance in Treatment of Chronic Heart Failure).
    Stevenson LW; Miller LW; Desvigne-Nickens P; Ascheim DD; Parides MK; Renlund DG; Oren RM; Krueger SK; Costanzo MR; Wann LS; Levitan RG; Mancini D;
    Circulation; 2004 Aug; 110(8):975-81. PubMed ID: 15313942
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanistic and clinical rationales for using beta-blockers in heart failure.
    Bristow MR
    J Card Fail; 2000 Jun; 6(2 Suppl 1):8-14. PubMed ID: 10908093
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Treatment of heart failure based on large-scale clinical trials: renin-angiotensin system antagonists and beta-blockers].
    Kubota T; Takeshita A
    Nihon Rinsho; 2003 May; 61(5):801-6. PubMed ID: 12755006
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Heart failure. Current pharmacologic treatment].
    Coma-Canella I; Castaño S; Nasarre E
    Rev Med Univ Navarra; 2005; 49(3):41-7. PubMed ID: 16400975
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel approach to the development of positive inotropic agents for chronic heart failure.
    Packer M
    J Cardiovasc Pharmacol; 1995; 26 Suppl 1():S52-6. PubMed ID: 8907131
    [TBL] [Abstract][Full Text] [Related]  

  • 17. What is the optimal medical management of ischemic heart failure?
    Cleland JG; Alamgir F; Nikitin NP; Clark AL; Norell M
    Prog Cardiovasc Dis; 2001; 43(5):433-55. PubMed ID: 11251129
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Is heart rate reduction beneficial to patients with heart insufficiency? Focus on beta-blockade].
    Henriksen OM; Gadsbøll N
    Ugeskr Laeger; 2002 Jan; 164(5):615-9. PubMed ID: 11871210
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The cellular and physiologic effects of beta blockers in heart failure.
    Sabbah HN
    Clin Cardiol; 1999 Oct; 22 Suppl 5():V16-20. PubMed ID: 10526699
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Beta blocker therapy, decompensated heart failure, and inotropic interactions: current perspectives.
    Zafrir B; Amir O
    Isr Med Assoc J; 2012 Mar; 14(3):184-9. PubMed ID: 22675861
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.